M0240 HCPCS Level II code: Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring, subsequent…
CMS terminated M0240: its last date of service was Dec 12, 2024. It stays here for looking up older claims; newer services need a current code.
Official description
M0240Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring, subsequent repeat doses
Short description: Casiri and imdev repeat
HCPCS · United States
Medicare details
The indicators CMS publishes with M0240 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Carrier judgment
- Medicare pricing
- Vaccinations
- Type of service
- Pneumococcal/flu vaccine
- BETOS category
- Immunizations/Vaccinations
- Added
- Jul 30, 2021
- Terminated after
- Dec 12, 2024
Where M0240 sits
- 1M codesMedical services and quality measures
- 2Terminated M0240Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring, subsequent repeat doses
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
Is HCPCS code M0240 still valid?
No. CMS terminated M0240; its last date of service was Dec 12, 2024. It is listed for looking up services from before then. Use a current code for newer services.
Does Medicare cover M0240?
CMS lists M0240’s Medicare coverage as “Carrier judgment” and its pricing as “Vaccinations”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside M0240
All M codesM0234Intravenous infusion, tocilizumab-aazg, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or…M0235Intravenous infusion, monoclonal antibody products with an indication for post-exposure prophylaxis or treatment of covid-19, for hospitalized adults and/or pediatric patients…M0236Intravenous infusion, monoclonal antibody products with an indication for post-exposure prophylaxis or treatment of covid-19, for hospitalized adults and/or pediatric patients…M0237Intravenous infusion, tocilizumab-anoh, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or…M0238Intravenous infusion, tocilizumab-anoh, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or…M0239Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoringM0241Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this…M0243Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoringM0244Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this…M0245Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoringM0246Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been…M0247Intravenous infusion, sotrovimab, includes infusion and post administration monitoring